Prelude Therapeutics Incorporated

Quanta Therapeutics, Inc.

Hong Lin

Juan Luengo

Michael Hawkins

Rupa S Shetty

Philip Michael Pitis

Gisela Saborit Villarroya

Audrey Hospital

Rupa Shetty

Neil Johnson

Jin Zeng

Andrew Paul Combs

Liang Lu

Pei Gan

Raul A Leal

Krishna Vaddi

The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

The disclosure is directed to methods of treatment using compounds of Formula (I).

Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (I-A), (I-B), (I-C), (I-C*), (I-D), (I-E), (I-F), (I-G), (I-H), (I-I), (I-J), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any one thereof. The compounds provided herein are useful for modulating KRAS G12D and/or other G12 mutants.

KRAS modulators and uses thereof

Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one there, useful for modulating KRAS GD12 and/or other G12 mutants.

Pyrimidine based modulators and uses thereof

Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (II), (II*), (III) or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modulating KRAS GD12 and/or other G12 mutants.

The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.

BRM targeting compounds and associated methods of use

The disclosure is directed to compounds of Formula (I) and Formula (II). Formula (I) and Formula (II) and pharmaceutically acceptable salts or solvates thereof. Pharmaceutical compositions comprising compounds of Formula (I) or Formula (II), as well as methods of their use and preparation, are also described. 

Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)

The disclosure is directed to compounds of Formula I  Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

The disclosure is directed to compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: Methods of their use in inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme and treating disease, as well as methods of their preparation are also described. 

Growing community of inventors

Exton, PA, United States of America

Hong Lin